Nuclear Medicine/Radiopharmaceuticals Market

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology,Cardiology), Procedures - Global Forecast to 2026

Report Code: PH 3590 Sep, 2021, by marketsandmarkets.com

[253 Pages Report] The nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8 billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

Nuclear Medicine/Radiopharmaceuticals Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the nuclear medicine market Market

Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The COVID-19 pandemic has led to major changes in the clinical operations of radiology departments worldwide. In parallel with clinical preparedness activities, academic medical centers and universities were rushed to shut down scientific research activities to maximize social distancing and minimize the spread of infection to research staff and others with whom they might have contact.

Nuclear medicine Market Dynamics

Drivers: Increasing incidence and prevalence of target conditions

The rising incidence and prevalence of cancer and cardiovascular disease (CVD) is a key factor supporting market growth. Most cases can be prevented through early detection and treatment; nuclear medicine plays a significant role in these areas. According to the WHO, cancer was the leading cause of death in 2020, accounting for nearly 10 million deaths. Annually, 19.3 million new cancer cases are expected to be reported worldwide by 2025. According to the WHO, globally, 17.9 million individuals died from CVD in 2019, accounting for 32% of the overall deaths globally. This figure is expected to reach 23.3 million by 2030. As nuclear medicine plays a significant role in disease diagnosis and treatment, the rising prevalence of these diseases is expected to drive the growth of the nuclear medicine market during the forecast period.

Restrains Short half-life of radiopharmaceuticals

The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and the content of the radionuclide. For example, the radioactivity of F-18 in PET scans decreases if not used within 110 minutes, while the radioactivity of C-11 decreases within 20 minutes. In SPECT diagnosis, the radioactivity of Tc-99m is reduced after six hours, while I-123 and In-111 isotopes should be utilized within 13 and 67 hours, respectively. The non-utilization of radioisotopes within the prescribed shelf life causes radiation and chemical decomposition, reducing radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy.

Opportunities: Use of radiopharmaceuticals in neurological applications

Nuclear medicine is majorly used for diagnosing CVD and cancers. The saturation of these markets has prompted a number of companies and stakeholders to focus on expanding the overall applications of radiopharmaceuticals. With the expanding application areas of radiopharmaceuticals, their demand and uptake are expected to increase in the coming years. This indicates an opportunity for players to expand their offerings and market shares by catering to the demand for radiopharmaceuticals in neurological applications.

Challenge: Hospital budget cuts and high equipment costs

The COVID-19 pandemic has created havoc worldwide; the outbreak has disrupted operations of healthcare systems globally. As a result, hospitals have ramped up testing efforts in an effort to save lives and minimize the spread of the virus. The financial challenges caused by COVID-19 forced governments across the globe to enforce budget cuts. Moreover, the pandemic resulted in lower patient volumes for nuclear medicine procedures and canceled elective procedures, creating a cash crunch for hospitals.

North America to witness significant growth from 2021 to 2026

North America is expected to account for the largest share of the nuclear medicine market in 2020, The large share of North America can be attributed to the development of novel technologies for radioisotope production, government funding, increasing R&D expenditure and company initiatives in the region.

Nuclear Medicine/Radiopharmaceuticals Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Cardinal Health (US),    GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacύbaώύ-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Million)

Segments covered

By Type, Application, Procedure volume & By Region

Geographies covered

North America, Europe, Asia Pacific, ROW

Companies covered

The major market players include Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacύbaώύ-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), JSC Isotope (Russia), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany). Major 25 players covered.

By Type

  • Diagnostic Nuclear Medicine
    • PECT Radiopharmaceuticals
      • Technetium-99m
      • Thallium-201
      • Gallium-67
      • Iodine-123
      • Other SPECT Isotopes
    • PET Radiopharmaceuticals
      • F-18
      • Ru-82
      • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
      • Ra-223
    • Beta Emitters
      • Iodine-131
      • Yttrium-90
      • Samarium-153
      • Lutetium-177
      • Rhenium-186
      • OtherBeta Emitters
  • Brachytherapy Isotopes
    • Iodine-125
    • Palladium-103
    • Cesium-131
    • Iridium-192
    • Other Brachytherapy Isotopes

By Applications

  • Diagnostic Applications
    • SPECT Applications
      • Cardiology
      • Bone Scans
      • Thyroid Applications
      • Pulmonary Scans
      • Other SPECT Applications
    • PET Applications
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
    • Therapeutic Applications
      • Thyroid Indications
      • Bone Metastasis
      • Lymphoma
      • Endocrine Tumors
      • Other Indications

By Procedural Volume Assessment

  • Diagnostic Procedures
    • SPECT Procedures
    • PET Procedures
  • Therapeutic Procedures
    • Beta Emitter Procedures
    • Alpha Emitter Procedures
    • Brachytherapy Procedures

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • Rest of APAC (RoAPAC)
  • RoW

Recent Developments

  • In 2021, Bracco entered into a partnership with CardioNavix which will help improve patient access to cardiac PET imaging.
  • In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 MARKET SCOPE
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
    2.2 RESEARCH METHODOLOGY STEPS
          FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
          FIGURE 2 RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Secondary sources
           2.2.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.2.2.1 Primary sources
                    2.2.2.2 Key insights from primary sources
           2.2.3 MARKET SIZE ESTIMATION METHODOLOGY
                    FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.4 REVENUE MAPPING-BASED MARKET ESTIMATION
    2.3 MARKET DATA ESTIMATION AND TRIANGULATION
          FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS OF THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 6 NUCLEAR MEDICINE MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 7 SPECT APPLICATIONS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 8 PET APPLICATIONS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET

4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 NUCLEAR MEDICINE MARKET OVERVIEW
          FIGURE 10 HIGH PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2020)
          FIGURE 11 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN NUCLEAR MEDICINE MARKET IN 2020
    4.3 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2021 VS. 2026
          FIGURE 12 SPECT PROCEDURES WILL CONTINUE TO DOMINATE THE DIAGNOSTIC PROCEDURES MARKET IN 2026

5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 13 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence and prevalence of target conditions
                    5.2.1.2 Development of alpha-radioimmunotherapy-based targeted cancer treatments
                    5.2.1.3 Initiatives to reduce the demand and supply gap of Mo-99
           5.2.2 RESTRAINTS
                    5.2.2.1 Short half-life of radiopharmaceuticals
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Use of radiopharmaceuticals in neurological applications
           5.2.4 CHALLENGES
                    5.2.4.1 Hospital budget cuts and high equipment costs
    5.3 IMPACT OF COVID-19 ON THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    5.4 VALUE CHAIN ANALYSIS
          FIGURE 14 VALUE CHAIN ANALYSIS OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    5.5 ECOSYSTEM COVERAGE
    5.6 REGULATORY LANDSCAPE
          TABLE 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: REGULATORY LANDSCAPE
    5.7 PORTER’S FIVE FORCES ANALYSIS
           5.7.1 PORTER’S FIVE FORCES ANALYSIS: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    5.8 PATENT ANALYSIS
          FIGURE 15 TOP 10 COMPANIES WITH THE HIGHEST NO. OF PATENT APPLICATIONS IN THE LAST 10 YEARS

6 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (Page No. - 65)
    6.1 INTRODUCTION
          TABLE 2 NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
    6.2 DIAGNOSTIC NUCLEAR MEDICINE
          TABLE 3 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 4 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 (USD MILLION)
          TABLE 5 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 6 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,  2019–2026 (USD MILLION)
          TABLE 7 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.1 SPECT RADIOPHARMACEUTICALS
                    TABLE 8 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES
                    TABLE 9 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 10 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 11 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 12 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 13 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.1 Tc-99m
                               6.2.1.1.1 Tc-99m commanded the largest share of the SPECT radiopharmaceuticals market in 2020
                                              TABLE 14 TC-99M MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 15 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 16 EUROPE: TC-99M MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 17 APAC: TC-99M MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.2 I-123
                               6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive the demand for I-123
                                              TABLE 18 I-123 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 19 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 20 EUROPE: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 21 APAC: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.3 Tl-201
                               6.2.1.3.1 TI-201 can be a potential substitute to Tc-99m
                                              TABLE 22 TI-201 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 23 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 24 EUROPE: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 25 APAC: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.4 Ga-67
                               6.2.1.4.1 Long half-life of Ga-67 facilitates easy sales and distribution
                                              TABLE 26 GA-67 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 27 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 28 EUROPE: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 29 APAC: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.5 Other SPECT isotopes
                                TABLE 30 OTHER SPECT ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 31 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 32 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 33 APAC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.2 PET RADIOPHARMACEUTICALS
                    TABLE 34 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 35 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 36 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 37 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 38 APAC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.1 F-18
                               6.2.2.1.1 F-18 commanded the largest share of the PET radiopharmaceuticals market in 2020
                                              TABLE 39 F-18 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 40 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 41 EUROPE: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 42 APAC: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.2 Rb-82
                               6.2.2.2.1 High accuracy offered by the Rb-82 isotope to support market growth
                                              TABLE 43 RB-82 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 44 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 45 EUROPE: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 46 APAC: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.3 Other PET isotopes
                                TABLE 47 OTHER PET ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 48 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 49 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 50 APAC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 THERAPEUTIC NUCLEAR MEDICINE
          TABLE 51 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 52 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 (USD MILLION)
          TABLE 53 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 54 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 55 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.1 ALPHA EMITTERS
                    6.3.1.1 Ra-223
                               6.3.1.1.1 Easy production of Ra-223 is a key advantage driving market growth
                                              TABLE 56 RA-223 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 57 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 58 EUROPE: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 59 APAC: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.2 BETA EMITTERS
                    TABLE 60 BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 61 BETA EMITTERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 62 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 63 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 64 APAC: BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.1 I-131
                               6.3.2.1.1 I-131 accounted for the largest share of the beta emitters market in 2020
                                              TABLE 65 I-131 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 66 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 67 EUROPE: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 68 APAC: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.2 Y-90
                               6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment
                                              TABLE 69 Y-90 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 70 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 71 EUROPE: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 72 APAC: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.3 Sm-153
                               6.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment
                                              TABLE 73 SM-153 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 74 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 75 EUROPE: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 76 APAC: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.4 Lu-177
                               6.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment
                                              TABLE 77 LU-177 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 78 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 79 EUROPE: LU-177 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 80 APAC: LU-177 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.5 Re-186
                               6.3.2.5.1 Re-186 is commonly used for bone pain relief
                                              TABLE 81 RE-186 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 82 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 83 EUROPE: RE-186 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 84 APAC: RE-186 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.6 Other beta emitters
                                TABLE 85 OTHER BETA EMITTERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 86 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 87 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 88 APAC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.3 BRACHYTHERAPY ISOTOPES
                    TABLE 89 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 90 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 91 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 92 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 93 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.3.1 I-125
                               6.3.3.1.1 I-125 accounted for the largest share of the brachytherapy isotopes market in 2020
                                              TABLE 94 I-125 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 95 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 96 EUROPE: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 97 APAC: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.3.2 Ir-192
                               6.3.3.2.1 Ir-192 is used in treating prostate, skin, and oral cancer
                                              TABLE 98 IR-192 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 99 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 100 EUROPE: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 101 APAC: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.3.3 Pd-103
                               6.3.3.3.1 Pd-103 is best suited to treat aggressive tumors
                                              TABLE 102 PD-103 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 103 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 104 EUROPE: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 105 APAC: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.3.4 Cesium-131
                               6.3.3.4.1 Cs-131 is commonly used in gynecological applications
                                              TABLE 106 CS-131 MARKET, BY REGION, 2019–2026 (USD MILLION)
                                              TABLE 107 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 108 EUROPE: CS-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                              TABLE 109 APAC: CS-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.3.5 Other brachytherapy isotopes
                                TABLE 110 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 111 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 112 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 113 APAC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION (Page No. - 112)
    7.1 INTRODUCTION
          TABLE 114 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    7.2 DIAGNOSTIC APPLICATIONS
          TABLE 115 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           7.2.1 SPECT APPLICATIONS
                    TABLE 116 SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 117 SPECT APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.1.1 Cardiology
                               7.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans
                                              TABLE 118 SPECT CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.1.2 Bone scans
                               7.2.1.2.1 Precision of SPECT in bone scans has driven the adoption of this technology
                                              TABLE 119 SPECT BONE SCAN APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.1.3 Thyroid
                               7.2.1.3.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment
                                              TABLE 120 SPECT THYROID APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.1.4 Pulmonary scans
                               7.2.1.4.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications
                                              TABLE 121 SPECT PULMONARY SCAN APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.1.5 Other SPECT applications
                                TABLE 122 OTHER SPECT APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 PET APPLICATIONS
                    TABLE 123 PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 124 PET APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.1 Oncology
                               7.2.2.1.1 Increasing incidence of cancer to propel market growth
                                              TABLE 125 PET ONCOLOGY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.2 Cardiology
                               7.2.2.2.1 Growing preference for FDG in cardiac imaging to boost the market growth
                                              TABLE 126 PET CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.3 Neurology
                               7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson’s disease is the major driver for the growth of the PET neurology market
                                              TABLE 127 PET NEUROLOGY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    7.2.2.4 Other PET applications
                                TABLE 128 OTHER PET APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 THERAPEUTIC APPLICATIONS
          TABLE 129 THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 130 THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.1 THYROID INDICATIONS
                    7.3.1.1 Increasing prevalence of thyroid disorders to fuel market growth
                                TABLE 131 THERAPEUTIC APPLICATIONS MARKET FOR THYROID INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
           7.3.2 BONE METASTASIS
                    7.3.2.1 Introduction of novel therapies for bone metastasis will positively impact market growth
                                TABLE 132 THERAPEUTIC APPLICATIONS MARKET FOR BONE METASTASIS, BY REGION, 2019–2026 (USD MILLION)
           7.3.3 ENDOCRINE TUMORS
                    7.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications
                                TABLE 133 THERAPEUTIC APPLICATIONS MARKET FOR ENDOCRINE TUMORS, BY REGION, 2019–2026 (USD MILLION)
           7.3.4 LYMPHOMA
                    7.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities
                                TABLE 134 THERAPEUTIC APPLICATIONS MARKET FOR LYMPHOMA, BY REGION, 2019–2026 (USD MILLION)
           7.3.5 OTHER THERAPEUTIC APPLICATIONS
                    TABLE 135 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)

8 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT (Page No. - 125)
    8.1 INTRODUCTION
          TABLE 136 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 137 NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
    8.2 DIAGNOSTIC PROCEDURES
           8.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH
                    TABLE 138 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 139 DIAGNOSTIC PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
           8.2.2 SPECT PROCEDURES
                    TABLE 140 SPECT PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 141 SPECT PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
           8.2.3 PET PROCEDURES
                    TABLE 142 PET PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 143 PET PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
    8.3 THERAPEUTIC PROCEDURES
           8.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH
                    TABLE 144 THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 145 THERAPEUTIC PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
           8.3.2 BETA-EMITTER PROCEDURES
                    TABLE 146 BETA-EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 147 BETA-EMITTER PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
           8.3.3 ALPHA-EMITTER PROCEDURES
                    TABLE 148 ALPHA-EMITTER PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
           8.3.4 BRACHYTHERAPY PROCEDURES
                    TABLE 149 BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 150 BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)

9 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION (Page No. - 132)
    9.1 INTRODUCTION
          TABLE 151 NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 16 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
          TABLE 152 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 153 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 154 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 155 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 156 NORTH AMERICA: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 157 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 158 NORTH AMERICA: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 159 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 160 NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 161 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 162 NORTH AMERICA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US dominates the North American nuclear medicine market
                                TABLE 163 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 164 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 165 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 166 US: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 167 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 168 US: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 169 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 170 US: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 171 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 172 US: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Investments to secure medical isotope supply are likely to boost the market growth
                                TABLE 173 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 174 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 175 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 176 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 177 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 178 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 179 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 180 CANADA: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 181 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 182 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.3 ASIA PACIFIC
          FIGURE 17 APAC: NUCLEAR MEDICINE MARKET SNAPSHOT
          TABLE 183 APAC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 184 APAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 185 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 186 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 187 APAC: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 188 APAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 189 APAC: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 190 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 191 APAC: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 192 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 193 APAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.3.1 JAPAN
                    9.3.1.1 Japan dominates the APAC nuclear medicine market
                                TABLE 194 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 195 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 196 JAPAN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 197 JAPAN: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 198 JAPAN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 199 JAPAN: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 200 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 201 JAPAN: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 202 JAPAN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 203 JAPAN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.3.2 CHINA
                    9.3.2.1 High incidence of cancer and stroke to support market growth in China
                                TABLE 204 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 205 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 206 CHINA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 207 CHINA: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 208 CHINA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 209 CHINA: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 210 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 211 CHINA: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 212 CHINA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 213 CHINA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.3.3 REST OF ASIA PACIFIC
                    TABLE 214 ROAPAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 215 ROAPAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 216 ROAPAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 217 ROAPAC: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 218 ROAPAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 219 ROAPAC: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 220 ROAPAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 221 ROAPAC: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 222 ROAPAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 223 ROAPAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.4 EUROPE
          TABLE 224 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 225 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 226 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 227 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 228 EUROPE: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 229 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 230 EUROPE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 231 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 232 EUROPE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 233 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 234 EUROPE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.1 GERMANY
                    9.4.1.1 Well-established healthcare system in Germany is a major factor supporting market growth
                                TABLE 235 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 236 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 237 GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 238 GERMANY: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 239 GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 240 GERMANY: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 241 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 242 GERMANY: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 243 GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 244 GERMANY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.2 FRANCE
                    9.4.2.1 France has a favorable reimbursement scenario for nuclear imaging
                                TABLE 245 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 246 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 247 FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 248 FRANCE: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 249 FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 250 FRANCE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 251 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 252 FRANCE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 253 FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 254 FRANCE: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           9.4.3 UK
                    9.4.3.1 Rising demand for nuclear imaging and growing awareness to drive market growth in the UK
                                TABLE 255 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 256 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 257 UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 258 UK: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 259 UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 260 UK: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 261 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 262 UK: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 263 UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 264 UK: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.4 ITALY
                    9.4.4.1 Growing prevalence of cancer and CVD to drive market growth in Italy
                                TABLE 265 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 266 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 267 ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 268 ITALY: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 269 ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 270 ITALY: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 271 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 272 ITALY: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 273 ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 274 ITALY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.5 SPAIN
                    9.4.5.1 Initiatives by SEMNIM will have a positive impact on the nuclear medicine market in Spain
                                TABLE 275 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 276 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 277 SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 278 SPAIN: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 279 SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 280 SPAIN: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 281 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 282 SPAIN: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 283 SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 284 SPAIN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.6 ROE
                    TABLE 285 ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 286 ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 287 ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 288 ROE: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 289 ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 290 ROE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 291 ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 292 ROE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 293 ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 294 ROE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.5 REST OF THE WORLD
          TABLE 295 ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 296 ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 297 ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 298 ROW: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 299 ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 300 ROW: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 301 ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 302 ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 303 ROW: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 192)
     10.1 OVERVIEW
             FIGURE 18 KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET
     10.2 MARKET RANKING ANALYSIS
             FIGURE 19 NUCLEAR MEDICINE MARKET: MARKET RANKING, 2020
     10.3 REVENUE ANALYSIS OF KEY MARKET PLAYERS
             FIGURE 20 REVENUE SHARE ANALYSIS OF KEY PLAYERS
     10.4 COMPANY EVALUATION MATRIX
             10.4.1 STARS
             10.4.2 EMERGING LEADERS
             10.4.3 PERVASIVE PLAYERS
             10.4.4 PARTICIPANTS
                        FIGURE 21 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (2020)
     10.5 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES
             10.5.1 PROGRESSIVE COMPANIES
             10.5.2 STARTING BLOCKS
             10.5.3 RESPONSIVE COMPANIES
             10.5.4 DYNAMIC COMPANIES
                        FIGURE 22 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES
     10.6 COMPETITIVE BENCHMARKING
             10.6.1 OVERALL FOOTPRINT OF KEY PLAYERS
                        TABLE 304 OVERALL FOOTPRINT OF KEY PLAYERS
                        TABLE 305 REGIONAL FOOTPRINT OF KEY PLAYERS
                        TABLE 306 PRODUCT FOOTPRINT OF KEY PLAYERS
     10.7 COMPETITIVE SCENARIO
             10.7.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 307 KEY PRODUCT LAUNCHES & APPROVALS
             10.7.2 DEALS
                        TABLE 308 KEY DEALS

11 COMPANY PROFILES (Page No. - 202)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
     11.1 MAJOR PLAYERS
             11.1.1 CURIUM
                        TABLE 309 CURIUM: BUSINESS OVERVIEW
             11.1.2 BRACCO IMAGING S.P.A.
                        TABLE 310 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW
             11.1.3 PHARMALOGIC
                        TABLE 311 PHARMALOGIC: BUSINESS OVERVIEW
             11.1.4 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
                        TABLE 312 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW
             11.1.5 CARDINAL HEALTH
                        TABLE 313 CARDINAL HEALTH: BUSINESS OVERVIEW
                        FIGURE 23 CARDINAL HEALTH: COMPANY SNAPSHOT (2020)
             11.1.6 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
                        TABLE 314 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW
             11.1.7 GE HEALTHCARE
                        TABLE 315 GE HEALTHCARE: BUSINESS OVERVIEW
                        FIGURE 24 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
             11.1.8 NORDION INC. (A SOTERA HEALTH COMPANY)
                        TABLE 316 NORDION INC.: BUSINESS OVERVIEW
             11.1.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
                        TABLE 317 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW
             11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
                        TABLE 318 NORTHSTAR MEDICAL RADIOISOTOPES LLC: BUSINESS OVERVIEW
             11.1.11 ECKERT & ZIEGLER
                        TABLE 319 ECKERT & ZIEGLER: BUSINESS OVERVIEW
                        FIGURE 25 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2020)
             11.1.12 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
                        TABLE 320 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE): BUSINESS OVERVIEW
             11.1.13 BAYER AG
                        TABLE 321 BAYER AG: BUSINESS OVERVIEW
                        FIGURE 26 BAYER AG: COMPANY SNAPSHOT (2020)
             11.1.14 SIEMENS HEALTHINEERS
                        TABLE 322 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
             11.1.15 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
                        TABLE 323 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW
             11.1.16 LANTHEUS MEDICAL IMAGING, INC.
                        TABLE 324 LANTHEUS MEDICAL IMAGING, INC.: BUSINESS OVERVIEW
                        FIGURE 27 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2020)
     11.2 OTHER PLAYERS
             11.2.1 GLOBAL MEDICAL SOLUTIONS
             11.2.2 SHINE MEDICAL TECHNOLOGIES
             11.2.3 ISOTOPIA MOLECULAR IMAGING LTD.
             11.2.4 SINOTAU PHARMACEUTICAL GROUP
             11.2.5 INSTITUTE OF ISOTOPES CO., LTD.
             11.2.6 CHINA ISOTOPE & RADIATION CORPORATION
             11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
             11.2.8 CYCLOPHARM
             11.2.9 IRE ELIT

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 244)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Nuclear Medicine/Radiopharmaceuticals Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

Report Objectives

  • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as agreements, collaborations, and partnerships; product deployments; product launches, enhancements, and integrations; acquisitions; and expansions in the nuclear medicine market

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

  • Additional country-level analysis of the nuclear medicine market.
  • Profiling of additional market players (up to 3)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Nuclear Medicine/Radiopharmaceuticals Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Nuclear Medicine/Radiopharmaceuticals Market

Request For Special Pricing
Report Code
PH 3590
Published ON
Sep, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine/Radiopharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved